Silexion Therapeutics Corp

Silexion Therapeutics Corp is a clinical-stage, oncology-focused biotechnology company dedicated to the discovery and development of proprietary treatments for cancers driven by mutations in the Kirsten rat sarcoma viral oncogene homolog (KRAS). The company, founded in 2008, is headquartered in Ramat-Gan, Israel.

Silexion Therapeutics leverages RNA interference (RNAi) based therapeutics and local extended-release biodegradable polymer microparticle delivery systems to target KRAS-driven solid tumors. Its lead product candidate, SIL-204, is designed to inhibit the KRAS oncogenic process in pancreatic cancer by delivering small interfering RNA (siRNA) to eliminate the messenger RNA (mRNA) of mutant KRAS oncogenes (G12V and G12D). SIL-204, an optimized version of its first-generation product LODER™ (siG12D-LODER), is intended for direct intratumoral administration, particularly in locally advanced pancreatic cancer.

In March 2026, Silexion Therapeutics received approval from the Israeli Ministry of Health to initiate a Phase 2/3 clinical trial for SIL-204 in locally advanced pancreatic cancer. The company also submitted a Phase 2/3 clinical trial application for SIL204 to Germany's BfArM in April 2026. Ilan Hadar serves as the Chairman of the Board and Chief Executive Officer, leading the company's efforts to position itself as a key player in precision oncology.